Wedbush increased their Q2 2025 earnings per share estimates for SpringWorks Therapeutics in a research report issued on Wednesday, February 12th. Wedbush analyst D. Nierengarten now expects that the ...

Stock analysts at HC Wainwright dropped their FY2024 earnings per share estimates for SpringWorks Therapeutics in a research note issued on Wednesday, February 12th. HC Wainwright analyst R. Burns now ...

Highlights,Financial firms maintain positive ratings for SpringWorks Therapeutics, with price targets reflecting growth ...

It was a busy week for the biotech sector, as the fourth-quarter earnings season is in full swing. While Gilead Sciences, Inc ...

This article summarizes the most significant insider buying and selling activities reported for Wednesday, February 12, 2025, ...

Representative Gilbert Ray Cisneros, Jr. (D-California) recently bought shares of Willis Towers Watson Public Limited (NASDAQ:WTW). In a filing disclosed on February 11th, the Representative disclosed ...

Islam Saqib, the Chief Executive Officer of SpringWorks Therapeutics, Inc. (NASDAQ:SWTX), sold 48,000 shares of the company's common stock on February 10, 2025. The sale comes as the stock trades near ...

Daniel Pichl, Chief People Officer at SpringWorks Therapeutics, Inc. (NASDAQ:SWTX), executed a series of stock transactions on February 10, 2025. Pichl sold a total of 29,750 shares of common stock, ...

Daniel Pichl, Chief People Officer at SpringWorks Therapeutics (NASDAQ:SWTX), has recently sold a significant portion of his holdings in the company. According to a Form 4 filing with the SEC, Pichl ...

Edris Badreddin, Chief Operating Officer of SpringWorks Therapeutics, Inc. (NASDAQ:SWTX), sold 30,000 shares of the company's ...